semaglutide discontinuation effects Once-Weekly in Adults with Overweight or Obesity Most quit breakthrough weight-loss drug

Initial shedding Increased hair fall in the first 2-4 weeks alarms many users

Semaglutide/Wegovy clinical trial alopecia incidence data (3% treatment vs

Already, at least 1 in 8 American adults [archived link] have taken a GLP-1 and more than half would qualify to take one, according to the latest estimates [archived link]

He stated, Semaglutide 2.4 mg not only reduces the first event risk but also lowers the cumulative cardiovascular burden making it a foundational therapy for secondary prevention in obesity-related cardiovascular disease Vince Lamanna, President of Novo Nordisk Canada, commented that these results expand the meaning of cardiovascular care by integrating obesity treatment as a proven strategy to prevent future events. He highlighted that Health Canadas decision to approve semaglutide 2.4 mg for patients with established CVD and overweight or obesity was the first global regulatory recognition of obesity therapy as a cardiovascular indication

Always consult with a healthcare professional before starting any new regimen

This includes individuals with severe anxiety or other psychological disorders, thyroid dysfunction, cardiovascular disease, and those who are pregnant or breastfeeding